SCHEMBL6697416

SCHEMBL6697416

COC(=O)c1cccc(OC)c1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.49
ITGA4 P13612 1/20 0.49
ADAMTS7 Q9UKP4 1/20 0.47
MAPT P10636 3/20 0.47
TP53 P04637 1/20 0.47
CFTR P13569 1/20 0.47
FABP3 P05413 1/20 0.45
FABP4 P15090 1/20 0.45
FABP5 Q01469 1/20 0.45
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
PDK2 Q15119 2/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
RXFP1 Q9HBX9 3/20 0.44
KDM4E B2RXH2 2/20 0.43
NCS1 P62166 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501691 0.87 FABP3 (0.52) ITGB1ITGA4ADAMTS7MAPTTP53
SCHEMBL13495445 0.87 MAPT (0.55) ITGB1ITGA4MAPTFABP3FABP4
SCHEMBL14585873 0.86 ITGB1 (0.47) ITGB1ITGA4ADAMTS7MAPTTP53
SCHEMBL4203346 0.84 MTTP (0.52) CFTRPDK2
SCHEMBL6705895 0.84 CFTR (0.48) ADAMTS7MAPTCFTRSLC6A4SLC6A3
SCHEMBL6704698 0.83 MRGPRX4 (0.49) ADAMTS7CFTRSLC6A4SLC6A3PDK2
SCHEMBL7174236 0.82 FABP4 (0.62) MAPTTP53CFTRFABP3FABP4
SCHEMBL1133231 0.82 AR (0.53) ITGB1ITGA4PDK2KDM4EHPGD
SCHEMBL6704771 0.81 CFTR (0.45) CFTRSLC6A4SLC6A3PDK2MRGPRX4
SCHEMBL18315876 0.80 TSHR (0.56) MAPTCFTRFABP3FABP4FABP5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656960-B2 Inhibitors of microsomal triglyceride transfer protein and apo-B secretion SURFACE LOGIX, INC. (US) 2017-05-23 US disclosed
US-9656960-B2 Inhibitors of microsomal triglyceride transfer protein and apo-B secretion SURFACE LOGIX, INC. (US) 2017-05-23 US disclosed
US-20160039765-A1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION KADMON CORPORATION, LLC 2016-02-11 US disclosed
US-20160039765-A1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION KADMON CORPORATION, LLC 2016-02-11 US disclosed
US-8980915-B2 Inhibitors of microsomal triglyceride transfer protein and apo-B secretion SURFACE LOGIX, INC. (US) 2015-03-17 US disclosed
US-8980915-B2 Inhibitors of microsomal triglyceride transfer protein and apo-B secretion SURFACE LOGIX, INC. (US) 2015-03-17 US disclosed
EP-1877369-B1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION SURFACE LOGIX INC (US) 2013-07-10 EP disclosed
US-20070027183-A1 Inhibitors of microsomal triglyceride transfer protein and apo-B secretion SURFACE LOGIX, INC. (US) 2007-02-01 US disclosed
US-20070027183-A1 Inhibitors of microsomal triglyceride transfer protein and apo-B secretion SURFACE LOGIX, INC. (US) 2007-02-01 US disclosed
US-20040044008-A1 Use of therapeutic benzamide derivatives DAUGAN ALAIN CLAUDE-MARIE (FR) 2004-03-04 US disclosed
US-6552022-B1 Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels SMITHKLINE BEECHAM CORPORATION 2003-04-22 US disclosed
EP-1286670-A2 USE OF THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-03-05 EP disclosed
WO-2001097810-A2 USE OF THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-12-27 WO disclosed
EP-1135378-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2001-09-26 EP disclosed
WO-2000032582-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2000-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039765-A1 INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND APO-B SECRETION APOB, CETP, MTTP ITGB1 4284/4885ITGA4 4661/4885ADAMTS7 2093/4885
US-20070027183-A1 Inhibitors of microsomal triglyceride transfer protein and apo-B secretion APOB, CETP, MTTP ITGB1 4284/4885ITGA4 4661/4885ADAMTS7 2093/4885
US-20040044008-A1 Use of therapeutic benzamide derivatives MTTP, LIPC, CETP ITGB1 4285/4885ITGA4 4308/4885ADAMTS7 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.